RE: Medical uses of CP - Part III

From: Sam Vanderstraeten (samvds@hotmail.com)
Date: Fri Feb 05 1999 - 01:25:23 PST


Date: Fri, 05 Feb 1999 01:25:23 PST
From: "Sam Vanderstraeten" <samvds@hotmail.com>
To: cp@opus.hpl.hp.com
Message-Id: <aabcdefg331$foo@default>
Subject: RE: Medical uses of CP - Part III

PART III

Provided that the above described rules are carried out on a regular
base
CARNIVORA (TM) treatment could be initiated according to the following
recommendations:

Introduction

CARNIVORA ( TM )

CARNIVORA (TM), a standardized phytopharmacon of pressed juices of
Dionaea muscipula, is used for the treatment of cancer and chronic
diseases
in man. Highest qualitiy is ensured by strict consideration of
GMP-guide-
lines resulting in extremely low endotoxin activities of less than 3.5
ng/ml.

In long and short term in-vivo and in-vitro studies CARNIVORA 9TM0
proved
to be completely untoxic and no-mutagenic. Studies carried out in
tissue
cultures, laboratory animals and in man, have revealed the folowing
therapeutic effects of CARNIVORA (TM):

1. cytostasis 2. Mitotic inhibition 3. Immunoinduction-Immunestimulation
and Modulation. 4. Starvation of the single tumor cell by decreasing
the ATP content. 5. Virucidal effect 6. Alleviation of pain

CARNIVORA (TM) has been proven to be asafe product and shows positive
effects in the treatment of cancer, chronic diseases and HIV infection
in man,

By combining silicagel column-chromatography preparative TLC, and HPLC
on ODS-phase various components were isolated from CARNIVORA (TM).

Kreher et Al. 1988 reported for the first time the isolation of
hydroplumbagin -4-0~ glucopyranoside, a component of this carnivorous
plant diontea muscipula,
component.

In a primary in vitro screening for anti-HIV activity in human
lymphocytes
 CARNIVORA (TM) proved to be highly efficacious. In this test the
concentration of the viral protein p24 is determined in the
supperrnatent of
HIV infected cells grown in the presence of CARNIVORA (TM).

Additionally, the concentration of viral RNA measured in the cells is a
good
indicator of virus replication. The anti viral effect is determined by
comparison of the p24- and RNA- concentrations in medicated and control
cells.

Result with CARNIVORA 9TM0: Inhibition of p24 -synthesis: 100%
                             Inhibition of RNA-synthesis:100%

In a pilot study on humans CARNIVORA (TM) demonstrates its effect in
regard
of improved Karnowsky index and body weight, decrease of beta 2 micro-
globulin, constant levels of neopterin, increase of CD4 helper cells and
total
T lymphocytes.

Toxicology:

Acute toxicity :
An acute toxicity study has been conducted in Spraque-Dawley rats, The
mean LD 50 ranged from 1500 mm to 1750 mg/ kg bw.

Subacute toxicity:
In a 90 day study CARNIVORA (TM) did not show any toxic reactions in
male
 rats at 30 times and An female rats at 60 times the recommended human
dose rate.

Mutagenicity and genotoxicity:
CARNIVORA (TM) was not mutagenic when assessed in the Ames test and
the chromosomal aberration test in the bone marrow of the Chinese
hamster.
There was no indication for genotoxicity when CARNIVORA (TM) was
evaluated
in the SOS- Chromotest.

Composition

The composition of CARNIVORA (TH) formulation is as follows:

CARNIVORA (TM) injectable solution

The 50 ml bottle contains the steril pressed juice of the entire fresh
plant,
 Dionaea muscipula, adjusted to 2% dry residue and isotonicity with
Mannitol.

CARNIVORA(TM) drops

1 ml CARNIVORA (TM) contains : The pressed juice of the entire fresh
plant,
Dionaea muscipula, adjusted to 2% (W/W) dry residue 0.33 ml, ethanol
86%,
and aqua purificata 0.34 mil.

Indications

The use of CARNIVORA ( TM ) Is reconmended for the treatment of the
following
diseases:

Adult malignant tumors (except Sarcomas )
Ulcerative colitis
Crohn\355s disease
Rheumatoid arthritis
Neurodermitis
Multiple sclerosis
Immune deficiency diseases
HIV lnfections, LAS, ARC:, AIDS
Chronic Fatigue Syndrom
Herpes labialis and urogenitalis

Dosage and treatment schedule:

Following are the recommendations for treatment with CARNIVORA 9TM0:

CARNIVORA (TM) 50 ml injectable solution

I.V. infusion: 3 to 5 ml CARNIVORA (TM) diluted in 250 ml 0.9 % NaCL
daily, Monday through Friday,

In Glioblastomas dilution should be with 250 ml Mannitol 10% instead of
NaCL.
The duration of the infusion should be 2 to 3 hours. After 2 to 3 weeks,
at
the time when a sudden decrease of the total T cells indicates an
overstimulation, the dosage has to be decreased and adjusted
individually.

In cases of urothel carcinomas instillations of 5 to l0 ml once per week
help
to prevent reoccurence, it applied up \353

I.M./ S.C. injections:
After 4 weeks intensive I.V. treatment long term intramuscular or
subcutaneous
injections should follow. The dosage should also be adjusted according
to the
results of the immune monitoring and clinical relevant markers.
According to
my experience the mean maintenance dosage range B is between 1 and 2 ml
s.c.
or i.m.

CARNIVORA (TM1 100 ml formulation)

Oral application:
Daily 3 to 5 times 50 drops before meals diluted in some water or tea.

The oral formulation should be applied in case of all tumors of the
intestinal
tract together with i.v, i.m. or s.c.

CARNIVORA (TM) treatment.
Patients Suffering from lung or bronchial cancer should inhale true
drops by
means of a cold vaporizer ( no ultrasound ) 3 to 5 times per day,(Mix 2
ml of
the oral formulation with 2 ml 0.9 % NaCL 3-5/day).

In HIV related diarrhea the drops are of additional benefit, also the
inhalations
in case of Aspergillus and Candida infections.

Dr. Med. Helmut Keller
Medical Director

Recommended Reading:
Balch, J.: Prescription for Nutritional Healing, Avery Publishing Group
Inc.
Garden Park NewYork .

Dostal, V.- et al.: Immunmonitoring and additive Immuntherapie,
Hippokrates
Verlag Stuttgart 1990 W-Germany

Keller, H.-Venusfliegenfallen - Extrakt hilft gegen Krebs, Arztliche
Praxis,
XXXVII. Jahrgang Nr. 36 1985 Werk- Verlag Dr. E. Banaschewski 8 Munchen
Grafelfing 1985 W- Germany

Keller,H.- Acta Empirica 1985, Band 34 Heft6, June 1995, Krebstherapie
mit einem pflanzlichen Wirkstoff-erst Erfahrungen mit einem neuen Phyto-
onkologicum, Karl F. Haug Verlag GmbH & Co. 6900 Heidelberg W Germany

Lane, W.-Sharks don\355t get cancer, Avery Publishing Group Inc. Garden
Park, New York 1992.

Wagner,H.-Structure elucidation of Plumbagin-analoges from Dionea
Muscipula
and their immunemodulating activities in vitro and in vivo. Sopron,
Hungary
August 24-27 1988

The CARNIYORA (TH) formulations can be ordered at the address Below .

Prices: 50 ml CARNIVORA (TM) .......................injectable DM:
$320.80
       100 ml CARNIVORA (TM) drops ...........................DM:
$177.55
       shlpping fee DM: 30.00 is not included.

Please make cheques payable to the address above.
It is our policy to receive payment before goods are sent out.
Fischer
Manager

Edgar Fischer, Manager
Carnivora-Forschungs-GmbH
Postfach 8, Lobensteiner Strasse 3
D-8646, Nordhalben, Germany
Phone: 011-49-9267-1662
Fax: 011-49-9267-1040

*** END PART III ***

Much greetings,

Sam Vanderstraeten.



This archive was generated by hypermail 2b30 : Tue Jan 02 2001 - 17:31:54 PST